Lancashire and South Cumbria
Formulary
Formulary
2 Cardiovascular system
02-11 Antifibrinolytic drugs and haemostatics
| Efanesoctocog alfa |
|
Formulary
|
For treatment and prevention of bleeding episodes in haemophilia A in people 2 years and over. |
 NICE TA1051: Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over |
|
| Marstacimab Hympavzi® |
|
Formulary
|
150mg/ml Pre-filled pens
For treatment of severe haemophilia B in people 12 years and over without anti-factor antibodies.
Marstacimab will be available via the Innovative Medicines Fund (IMF) from the date of stock availability, currently expected w/c 23 June 2025, in line with these recommendations and according to a set of treatment criteria which translates the NICE recommendation into a clinical guide as to use in practice.
NHS England will then routinely commission marstacimab in patients with haemophilia B via commissioned haemophilia comprehensive care centres. |
|
NICE GID-TA11397: Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over |
|
|
| Tranexamic Acid |
|
Formulary
|
| Injection 500mg/5mL |
|
NICE NG39: Major trauma: assessment and initial management |
|
|
Links
BCSH Guidelines - heritable thrombophilia
Enoxaparin Shared Care Guideline **FOR USE IN THE MORECAMBE BAY REGION ONLY**- Low Molecular Weight Heparins - Use in Primary care Best Practice Guideline *FOR USE IN PENNINE REGION ONLY*
- LSCMMG: Atrial Fibrillation Pathway for the prevention of stroke and systemic embolism in AF in the absence of valvular heart disease
- LSCMMG: Heart Failure - Primary Care Guideline for the Use of SGLT-2 Inhibitors in Reduced Ejection Fraction Heart Failure
- LSCMMG: Lipid Management Pathway for Primary Prevention of Cardiovascular Disease
- LSCMMG: Lipid Management Pathway for Secondary Prevention of Cardiovascular Disease
- LSCMMG: Low Molecular Weight Heparins (LMWHs) Summary Prescribing Guide
- Manufacturers data sheet
- Manufacturers data sheet (SPC)
- MHRA withdrawal information
- MHRA: Clopidogrel and proton pump inhibitors: interaction—updated advice
- NG 185 - Acute coronary syndromes
- NG 196 - Atrial fibrillation: diagnosis and management
- NICE GID-TA11397: Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over
- NICE NG106: Chronic heart failure in adults: diagnosis and management
- NICE NG136: Hypertension in adults: diagnosis and management
- NICE NG187: Acute heart failure: diagnosis and management
- NICE NG203: Chronic kidney disease: assessment and management
- NICE NG39: Major trauma: assessment and initial management
- NICE NG95: Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis
- NICE TA1051: Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over